PHGE - BiomX Inc.
6.3
1.430 22.698%
Share volume: 126,138
Last Updated: 03-04-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.44%
PREVIOUS CLOSE
CHG
CHG%
$4.87
1.43
0.29%
Fundamental analysis
5%
Profitability
0%
Dept financing
2%
Liquidity
50%
Performance
0%
Performance
5 Days
47.54%
1 Month
38.16%
3 Months
21.86%
6 Months
1,118.57%
1 Year
872.37%
2 Year
2,626.09%
Key data
Stock price
$6.30
DAY RANGE
$4.56 - $6.49
52 WEEK RANGE
$0.24 - $8.50
52 WEEK CHANGE
$899.52
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-19-2025
Company detail
CEO: Jonathan E. Solomon
Region: US
Website: biomx.com
Employees: 120
IPO year: 2019
Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
Region: US
Website: biomx.com
Employees: 120
IPO year: 2019
Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
BiomX Inc. develops products using natural and engineered phage technologies to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC) The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S.Aureus), a bacteria associated
Recent news